EXCLUSIVE-US FDA taps Merck drugs with blockbuster sales potential for national priority vouchers
The U.S. FDA is fast-tracking reviews for Merck's experimental drugs, enlicitide and sac-TMT, under the National Priority Voucher program. These drugs, with potential multibillion-dollar sales, are expected to have applications submitted in 2026. The program aims to expedite FDA decisions for drugs with significant public health impacts, reducing review times to one or two months. Merck's enlicitide, a cholesterol pill, and sac-TMT, a cancer therapy, are anticipated to generate substantial sales, with sac-TMT potentially exceeding $10 billion annually.
